The efficacy of interleukin-6 inhibitor tocilizumab for takayasu’s arteritis, after insufficient response to previous treatment with glucocorticoids, methotrexate, cyclophosphamide, fludarabine. (A case report)

The efficacy of interleukin-6 inhibitor tocilizumab for takayasu’s arteritis, after insufficient response to previous treatment with glucocorticoids, methotrexate, cyclophosphamide, fludarabine. (A case report)

Thanks to progress in understanding of Takayasu’s arteritis pathogenesis, the role of biological therapies is expanding, especially in refractory diseases. Robust data are still lacking to draw conclusions concerning the use of interleukin (IL)-6 inhibitors in Takayasu’s arteritis. The article prese...

Full description

Bibliographic Details
Main Authors: V. N. Antipova, L. V. Solodovnikova, T. V. Beketova
Format: Article
Language:Russian
Published: IMA PRESS LLC 2021-01-01
Series:Научно-практическая ревматология
Subjects:
takayasu’s arteritis
biologics
interleukin-6
tocilizumab
Online Access:https://rsp.mediar-press.net/rsp/article/view/2976

Internet

https://rsp.mediar-press.net/rsp/article/view/2976

Similar Items